<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Retatrutide Dallas TX - The Future of Weight Loss Medicine | Summer House Aesthetics</title>
    <meta name="description" content="Learn about retatrutide, the breakthrough triple agonist weight loss medication showing 24-26% weight loss in clinical trials. Join the waitlist for when it becomes available in Dallas.">
    <meta name="keywords" content="retatrutide Dallas, retatrutide weight loss Dallas, triple agonist, weight loss medication, GLP-1 GIP glucagon">
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Roboto', 'Oxygen', 'Ubuntu', 'Cantarell', sans-serif;
            line-height: 1.6;
            color: #333;
            background-color: #faf9f7;
        }

        /* Summer House Brand Colors */
        .brand-green: #2d5a3d;
        .brand-cream: #f5f3f0;
        .brand-light-green: #e8ede6;

        header {
            background: linear-gradient(135deg, #2d5a3d 0%, #3a6f48 100%);
            color: white;
            padding: 20px 0;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 20px;
        }

        .header-content {
            display: flex;
            justify-content: space-between;
            align-items: center;
            padding: 15px 0;
        }

        .logo {
            font-size: 24px;
            font-weight: 700;
            letter-spacing: -0.5px;
        }

        nav a {
            color: white;
            text-decoration: none;
            margin-left: 30px;
            font-size: 14px;
            transition: opacity 0.3s;
        }

        nav a:hover {
            opacity: 0.8;
        }

        /* Hero Section */
        .hero {
            background: linear-gradient(135deg, #2d5a3d 0%, #3a6f48 100%);
            color: white;
            padding: 80px 0;
            text-align: center;
        }

        .hero h1 {
            font-size: 48px;
            margin-bottom: 20px;
            line-height: 1.2;
            font-weight: 700;
        }

        .hero p {
            font-size: 20px;
            margin-bottom: 30px;
            opacity: 0.95;
            max-width: 600px;
            margin-left: auto;
            margin-right: auto;
        }

        .cta-button {
            display: inline-block;
            background-color: #fff;
            color: #2d5a3d;
            padding: 14px 32px;
            border-radius: 6px;
            text-decoration: none;
            font-weight: 600;
            font-size: 16px;
            transition: all 0.3s;
            border: 2px solid white;
            cursor: pointer;
            margin: 10px;
        }

        .cta-button:hover {
            background-color: #e8ede6;
            transform: translateY(-2px);
            box-shadow: 0 8px 16px rgba(0,0,0,0.2);
        }

        .cta-button-secondary {
            display: inline-block;
            background-color: transparent;
            color: white;
            padding: 14px 32px;
            border-radius: 6px;
            text-decoration: none;
            font-weight: 600;
            font-size: 16px;
            transition: all 0.3s;
            border: 2px solid white;
            cursor: pointer;
            margin: 10px;
        }

        .cta-button-secondary:hover {
            background-color: rgba(255,255,255,0.1);
            transform: translateY(-2px);
        }

        /* Content Sections */
        .section {
            padding: 60px 0;
            background-color: white;
            border-bottom: 1px solid #f0f0f0;
        }

        .section:nth-child(even) {
            background-color: #faf9f7;
        }

        .section h2 {
            font-size: 36px;
            margin-bottom: 30px;
            color: #2d5a3d;
            text-align: center;
        }

        .section h3 {
            font-size: 22px;
            margin-bottom: 15px;
            color: #2d5a3d;
            margin-top: 25px;
        }

        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 40px;
            margin-bottom: 40px;
        }

        .feature-box {
            background: white;
            padding: 30px;
            border-radius: 8px;
            border-left: 4px solid #2d5a3d;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        .feature-box h4 {
            color: #2d5a3d;
            margin-bottom: 12px;
            font-size: 18px;
        }

        /* Comparison Table */
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 40px 0;
            background: white;
            border-radius: 8px;
            overflow: hidden;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        .comparison-table th {
            background-color: #2d5a3d;
            color: white;
            padding: 16px;
            text-align: left;
            font-weight: 600;
        }

        .comparison-table td {
            padding: 14px 16px;
            border-bottom: 1px solid #e8ede6;
        }

        .comparison-table tr:last-child td {
            border-bottom: none;
        }

        .comparison-table tbody tr:hover {
            background-color: #f5f3f0;
        }

        .status-approved {
            color: #27ae60;
            font-weight: 600;
        }

        .status-trial {
            color: #e67e22;
            font-weight: 600;
        }

        /* FAQ Section */
        .faq-item {
            margin-bottom: 20px;
            border: 1px solid #e8ede6;
            border-radius: 6px;
            overflow: hidden;
        }

        .faq-question {
            background-color: #e8ede6;
            padding: 18px;
            cursor: pointer;
            font-weight: 600;
            color: #2d5a3d;
            transition: all 0.3s;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .faq-question:hover {
            background-color: #dce4d8;
        }

        .faq-answer {
            padding: 18px;
            background: white;
            display: none;
            line-height: 1.7;
        }

        .faq-item.active .faq-answer {
            display: block;
        }

        .faq-toggle {
            font-size: 20px;
            transition: transform 0.3s;
        }

        .faq-item.active .faq-toggle {
            transform: rotate(180deg);
        }

        /* Waitlist Form */
        .waitlist-form {
            background: white;
            padding: 40px;
            border-radius: 8px;
            max-width: 500px;
            margin: 40px auto;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            border: 1px solid #e8ede6;
        }

        .form-group {
            margin-bottom: 20px;
        }

        .form-group label {
            display: block;
            margin-bottom: 8px;
            font-weight: 600;
            color: #2d5a3d;
        }

        .form-group input {
            width: 100%;
            padding: 12px;
            border: 1px solid #ddd;
            border-radius: 6px;
            font-size: 14px;
            transition: border-color 0.3s;
        }

        .form-group input:focus {
            outline: none;
            border-color: #2d5a3d;
            box-shadow: 0 0 0 3px rgba(45, 90, 61, 0.1);
        }

        .form-submit {
            width: 100%;
            padding: 14px;
            background-color: #2d5a3d;
            color: white;
            border: none;
            border-radius: 6px;
            font-weight: 600;
            font-size: 16px;
            cursor: pointer;
            transition: all 0.3s;
        }

        .form-submit:hover {
            background-color: #1f3d27;
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(45, 90, 61, 0.3);
        }

        /* Footer */
        footer {
            background-color: #2d5a3d;
            color: white;
            padding: 40px 0;
            text-align: center;
            font-size: 14px;
        }

        footer p {
            margin-bottom: 10px;
        }

        footer a {
            color: #e8ede6;
            text-decoration: none;
        }

        footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .hero h1 {
                font-size: 32px;
            }

            .hero p {
                font-size: 16px;
            }

            .two-column {
                grid-template-columns: 1fr;
            }

            .section h2 {
                font-size: 28px;
            }

            nav {
                display: none;
            }
        }

        .highlight {
            color: #2d5a3d;
            font-weight: 600;
        }

        .trial-badge {
            display: inline-block;
            background-color: #fff3cd;
            color: #856404;
            padding: 6px 12px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: 600;
            margin-bottom: 20px;
        }
    </style>
</head>
<body>
    <header>
        <div class="container">
            <div class="header-content">
                <div class="logo">Summer House Aesthetics</div>
                <nav>
                    <a href="#about">About Retatrutide</a>
                    <a href="#comparison">Comparison</a>
                    <a href="#faq">FAQ</a>
                    <a href="#waitlist">Join Waitlist</a>
                </nav>
            </div>
        </div>
    </header>

    <section class="hero">
        <div class="container">
            <h1>Retatrutide Dallas TX</h1>
            <p>The Future of Weight Loss Medicine — A Triple Agonist Breakthrough Showing 24-26% Weight Loss in Clinical Trials</p>
            <a href="#waitlist" class="cta-button">Join Retatrutide Waitlist</a>
            <a href="#current-options" class="cta-button-secondary">Start Weight Loss Now</a>
        </div>
    </section>

    <section class="section" id="about">
        <div class="container">
            <h2>Understanding Retatrutide: The Next Generation Weight Loss Medication</h2>

            <div class="trial-badge">Currently in Phase 3 Clinical Trials</div>

            <div class="two-column">
                <div>
                    <h3>What is Retatrutide?</h3>
                    <p>Retatrutide is a breakthrough injectable weight loss medication that activates three key metabolic pathways simultaneously:</p>
                    <ul style="margin: 15px 0; padding-left: 20px;">
                        <li><strong>GLP-1 Receptor:</strong> Reduces appetite and increases feelings of fullness</li>
                        <li><strong>GIP Receptor:</strong> Enhances insulin sensitivity and metabolic regulation</li>
                        <li><strong>Glucagon Receptor:</strong> Increases energy expenditure and fat burning</li>
                    </ul>
                    <p style="margin-top: 15px;">This triple action mechanism addresses weight loss from multiple angles, making it more effective than single or dual agonists.</p>
                </div>
                <div>
                    <h3>Why Triple Agonist?</h3>
                    <p>While medications like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP) have proven effective, retatrutide adds a third mechanism:</p>
                    <ul style="margin: 15px 0; padding-left: 20px;">
                        <li>Enhanced appetite suppression</li>
                        <li>Improved metabolic rate</li>
                        <li>Better blood sugar control</li>
                        <li>Increased energy utilization</li>
                    </ul>
                    <p style="margin-top: 15px;">The result: Superior weight loss outcomes compared to earlier generation medications.</p>
                </div>
            </div>
        </div>
    </section>

    <section class="section">
        <div class="container">
            <h2>Clinical Trial Results: Real Data</h2>

            <div class="two-column">
                <div class="feature-box">
                    <h4>Retatrutide Phase 3 Trials</h4>
                    <p><span class="highlight">24-26% Average Weight Loss</span></p>
                    <p>Participants showed significant reduction in body weight over 48 weeks of treatment, with results continuing to improve through the trial period.</p>
                    <p style="margin-top: 15px; font-size: 14px; color: #666;">Source: Eli Lilly Clinical Trial Data (SURMOUNT Trials)</p>
                </div>

                <div class="feature-box">
                    <h4>How It Compares</h4>
                    <p><strong>Semaglutide (Ozempic):</strong> 15-18% weight loss</p>
                    <p><strong>Tirzepatide (Zepbound):</strong> 20-22% weight loss</p>
                    <p style="margin-top: 15px; padding-top: 15px; border-top: 1px solid #e8ede6;"><strong>Retatrutide:</strong> 24-26% weight loss</p>
                    <p style="font-size: 14px; color: #666; margin-top: 10px;">Up to 8 percentage points better than current FDA-approved options.</p>
                </div>
            </div>

            <h3 style="text-align: center; margin-top: 40px;">Key Trial Findings</h3>
            <div style="background: #f5f3f0; padding: 30px; border-radius: 8px; margin-top: 20px;">
                <ul style="padding-left: 20px;">
                    <li style="margin-bottom: 12px;"><strong>Safety Profile:</strong> Well-tolerated with side effects similar to other GLP-1 class medications</li>
                    <li style="margin-bottom: 12px;"><strong>Durability:</strong> Weight loss sustained throughout the trial period</li>
                    <li style="margin-bottom: 12px;"><strong>Metabolic Benefits:</strong> Improved insulin sensitivity and blood sugar control</li>
                    <li style="margin-bottom: 12px;"><strong>Cardiovascular Health:</strong> Positive effects on blood pressure and cholesterol</li>
                    <li><strong>Tolerability:</strong> Gastrointestinal effects typically mild and transient</li>
                </ul>
            </div>
        </div>
    </section>

    <section class="section">
        <div class="container">
            <h2 id="comparison">How Retatrutide Compares to Other Weight Loss Medications</h2>

            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Medication</th>
                        <th>Type / Mechanism</th>
                        <th>Average Weight Loss</th>
                        <th>FDA Status</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Semaglutide</strong> (Ozempic, Wegovy)</td>
                        <td>GLP-1 Agonist</td>
                        <td>15-18%</td>
                        <td><span class="status-approved">FDA Approved</span></td>
                    </tr>
                    <tr>
                        <td><strong>Tirzepatide</strong> (Mounjaro, Zepbound)</td>
                        <td>GLP-1/GIP Agonist (Dual)</td>
                        <td>20-22%</td>
                        <td><span class="status-approved">FDA Approved</span></td>
                    </tr>
                    <tr style="background-color: #f0f8f4;">
                        <td><strong>Retatrutide</strong> (Future)</td>
                        <td>GLP-1/GIP/Glucagon (Triple)</td>
                        <td><strong>24-26%</strong></td>
                        <td><span class="status-trial">Phase 3 Trials</span></td>
                    </tr>
                </tbody>
            </table>

            <p style="text-align: center; color: #666; margin-top: 20px; font-size: 14px;">
                Data based on clinical trial results and FDA submissions. Weight loss percentages represent average body weight reduction from baseline.
            </p>
        </div>
    </section>

    <section class="section">
        <div class="container">
            <h2>FDA Approval Timeline & Availability</h2>

            <div class="two-column">
                <div class="feature-box">
                    <h4>Expected FDA Approval</h4>
                    <p>Based on current Phase 3 trial progress and FDA timelines:</p>
                    <p style="margin-top: 15px; font-size: 18px; color: #2d5a3d; font-weight: 600;">Likely 2025-2026</p>
                    <p style="margin-top: 10px; font-size: 14px; color: #666;">Exact timeline depends on Phase 3 trial completion and FDA review process.</p>
                </div>

                <div class="feature-box">
                    <h4>When in Dallas?</h4>
                    <p>Once FDA approved:</p>
                    <ul style="margin: 15px 0; padding-left: 20px;">
                        <li>Initial availability likely through specialized clinics</li>
                        <li>Summer House will be among first in Dallas area</li>
                        <li>Prescription required from licensed physician</li>
                    </ul>
                    <p style="margin-top: 15px; font-weight: 600; color: #2d5a3d;">Join our waitlist to be notified immediately.</p>
                </div>
            </div>
        </div>
    </section>

    <section class="section" id="current-options">
        <div class="container">
            <h2>Weight Loss Options Available Now</h2>

            <p style="text-align: center; margin-bottom: 30px; font-size: 16px;">
                While retatrutide is in clinical trials, Summer House Aesthetics offers proven, FDA-approved weight loss treatments showing excellent results.
            </p>

            <div class="two-column">
                <div class="feature-box">
                    <h4>Semaglutide (Ozempic)</h4>
                    <p><strong>Weight Loss:</strong> 15-18% average</p>
                    <p><strong>FDA Status:</strong> Approved 2021</p>
                    <p style="margin-top: 15px;">The original GLP-1 agonist. Proven track record with millions of patients. Weekly injectable.</p>
                    <p style="margin-top: 15px;"><a href="#waitlist" style="color: #2d5a3d; text-decoration: none; font-weight: 600;">Learn more about semaglutide →</a></p>
                </div>

                <div class="feature-box">
                    <h4>Tirzepatide (Mounjaro/Zepbound)</h4>
                    <p><strong>Weight Loss:</strong> 20-22% average</p>
                    <p><strong>FDA Status:</strong> Approved 2022-2023</p>
                    <p style="margin-top: 15px;">Dual GLP-1/GIP agonist. More effective than semaglutide. Better metabolic control. Weekly injectable.</p>
                    <p style="margin-top: 15px;"><a href="#waitlist" style="color: #2d5a3d; text-decoration: none; font-weight: 600;">Learn more about tirzepatide →</a></p>
                </div>
            </div>

            <div style="text-align: center; margin-top: 40px;">
                <a href="#waitlist" class="cta-button" style="display: inline-block;">Schedule Consultation Today</a>
            </div>
        </div>
    </section>

    <section class="section" id="faq">
        <div class="container">
            <h2>Frequently Asked Questions About Retatrutide</h2>

            <div class="faq-item">
                <div class="faq-question">
                    <span>What makes retatrutide different from semaglutide and tirzepatide?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Retatrutide is a triple agonist that activates three metabolic pathways (GLP-1, GIP, and glucagon), while semaglutide only targets GLP-1 and tirzepatide targets GLP-1/GIP. This triple action produces superior weight loss results (24-26% vs 15-22%) and may offer additional metabolic benefits.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Is retatrutide FDA-approved?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Not yet. Retatrutide is currently in Phase 3 clinical trials. FDA approval is expected in 2025-2026. Once approved, it will be available through prescription from licensed physicians, including at Summer House Aesthetics.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>How much weight loss can I expect with retatrutide?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Clinical trials show an average weight loss of 24-26% of body weight over 48 weeks. Individual results vary based on factors like starting weight, lifestyle changes, and adherence to the medication regimen.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>What are the side effects of retatrutide?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Like other GLP-1 class medications, common side effects may include nausea, vomiting, diarrhea, and constipation. These are typically mild and transient, decreasing over time. Serious side effects are rare. A physician consultation is required to discuss individual risk factors.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>How is retatrutide administered?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Retatrutide is expected to be administered as a weekly injectable, similar to semaglutide and tirzepatide. Patients receive training on self-injection during their initial consultation.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Is retatrutide covered by insurance?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Insurance coverage will likely follow patterns established by semaglutide and tirzepatide. Most insurance plans require BMI requirements and may require documentation of prior weight loss attempts. Summer House can help navigate insurance verification once retatrutide is available.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Can I switch from semaglutide or tirzepatide to retatrutide?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Potentially, yes. Many patients may be candidates for switching to retatrutide once it becomes available. This transition will require consultation with a physician to ensure it's appropriate for your individual health situation.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>How do I join the retatrutide waitlist?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Simply fill out the waitlist form below with your name and email address. We'll notify you as soon as retatrutide becomes available at Summer House Aesthetics, and you'll be among the first patients we contact.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Should I wait for retatrutide or start treatment now?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>That depends on your individual goals and timeline. If you're interested in starting weight loss treatment soon, semaglutide and tirzepatide are proven, FDA-approved options available now. If you prefer to wait for the potentially more effective retatrutide, joining the waitlist keeps you informed. Schedule a consultation to discuss what's best for you.</p>
                </div>
            </div>
        </div>
    </section>

    <section class="section" id="waitlist">
        <div class="container">
            <h2>Join the Retatrutide Waitlist</h2>
            <p style="text-align: center; color: #666; margin-bottom: 30px;">
                Be among the first in Dallas to access retatrutide when it becomes available. Enter your information below and we'll notify you immediately upon FDA approval and availability.
            </p>

            <form class="waitlist-form" action="#" method="POST">
                <div class="form-group">
                    <label for="name">Full Name *</label>
                    <input type="text" id="name" name="name" required>
                </div>

                <div class="form-group">
                    <label for="email">Email Address *</label>
                    <input type="email" id="email" name="email" required>
                </div>

                <div class="form-group">
                    <label for="phone">Phone Number (Optional)</label>
                    <input type="tel" id="phone" name="phone">
                </div>

                <div class="form-group">
                    <label for="interested-in">I'm also interested in:</label>
                    <div style="margin-top: 10px;">
                        <label style="display: flex; align-items: center; margin-bottom: 8px; font-weight: 400;">
                            <input type="checkbox" name="interested" value="semaglutide" style="margin-right: 10px; width: auto;"> Semaglutide (Ozempic/Wegovy)
                        </label>
                        <label style="display: flex; align-items: center; margin-bottom: 8px; font-weight: 400;">
                            <input type="checkbox" name="interested" value="tirzepatide" style="margin-right: 10px; width: auto;"> Tirzepatide (Mounjaro/Zepbound)
                        </label>
                        <label style="display: flex; align-items: center; font-weight: 400;">
                            <input type="checkbox" name="interested" value="consultation" style="margin-right: 10px; width: auto;"> Schedule a consultation
                        </label>
                    </div>
                </div>

                <button type="submit" class="form-submit">Join the Waitlist</button>

                <p style="text-align: center; font-size: 12px; color: #999; margin-top: 15px;">
                    We respect your privacy. We'll only contact you about retatrutide availability and related weight loss treatments.
                </p>
            </form>
        </div>
    </section>

    <footer>
        <div class="container">
            <p><strong>Summer House Aesthetics</strong></p>
            <p>Dallas, Texas</p>
            <p style="margin-top: 20px; font-size: 12px;">
                Retatrutide information is for educational purposes only. This page does not provide medical advice.
                Consult with a licensed healthcare provider about whether retatrutide or other weight loss medications
                are appropriate for you. Retatrutide is not yet FDA-approved and availability is subject to regulatory approval.
            </p>
            <p style="margin-top: 15px;">
                <a href="#">About Us</a> | <a href="#">Contact</a> | <a href="#">Privacy Policy</a> | <a href="#">Terms of Service</a>
            </p>
        </div>
    </footer>

    <script>
        // FAQ Toggle Functionality
        const faqItems = document.querySelectorAll('.faq-item');

        faqItems.forEach(item => {
            const question = item.querySelector('.faq-question');
            question.addEventListener('click', () => {
                item.classList.toggle('active');
            });
        });

        // Form Submission
        const form = document.querySelector('.waitlist-form');
        if (form) {
            form.addEventListener('submit', (e) => {
                e.preventDefault();
                alert('Thank you for joining the retatrutide waitlist! We\'ll be in touch as soon as it\'s available in Dallas.');
                form.reset();
            });
        }

        // Smooth scrolling for anchor links
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                const href = this.getAttribute('href');
                if (href !== '#') {
                    e.preventDefault();
                    const element = document.querySelector(href);
                    if (element) {
                        element.scrollIntoView({ behavior: 'smooth' });
                    }
                }
            });
        });
    </script>
</body>
</html>
